Gastrointestinal Cancer News

CHICAGO — Dawn L. Hershman, MD, MS, associate professor of medicine at Columbia University Medical Center, reviews study results that identified comorbidities and lifestyle-related factors that can predict chemotherapy-induced peripheral neuropathy risk at the ASCO Annual Meeting.

An analysis of volatile organic compounds emitted from stool showed superior diagnostic utility for identifying colorectal adenocarcinoma compared with other fecal biomarkers, according to data presented at the British Society of Gastroenterology Annual Meeting.

In a randomized clinical trial, a group of international researchers evaluated colonoscopy screening for the first time, according to recent findings published in JAMA Internal Medicine.

Patients who started taking aspirin after receiving a diagnosis of colorectal cancer demonstrated improved OS and cancer-specific survival, according to the results of retrospective cohort study conducted in Norway.

Patients with advanced cancer and their caregivers perceived palliative care negatively and associated it with end-of-life care, according to the results of a secondary qualitative analysis.

Employees of SLACK Incorporated — publisher of HemOnc Today — wore white today in support of White Out Cancer Day.

The prevalence and incidence of colorectal cancer among patients with inflammatory bowel disease is less than 3% after colectomy and less than 1% after ileal pouch-anal anastomosis, according to the results of a systematic review and meta-analysis.

CHICAGO — Stephen B. Gruber, MD, PhD, MPH, director of the USC Norris Comprehensive Cancer Center, discusses studies that show multiplex panel testing is efficacious and safe for patients and their families at the ASCO Annual Meeting.

Coffee no longer should be classified as carcinogenic to humans, according to a working group from WHO’s International Agency for Research on Cancer.

Taking Decadron combined with Emend prior to drug eluting bead transarterial chemoembolization helped prevent postembolization syndrome posttreatment in patients with hepatocellular carcinoma, according to findings presented at the World Conference on Interventional Oncology.